Why this beaten-up FTSE 100 dividend stock could be a bargain

Roland Head explains why he’d buy this 6% yielder from the FTSE 100 (INDEXFTSE:UKX).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m going to look at two beaten-up big cap stocks. For various reasons, both companies are out of favour at the moment. But I believe both have the potential to deliver a rapid rebound.

A special case

Shares of pharmaceutical group Indivior (LSE: INDV) fell more than 35% in one day at the end of August, when the company lost a key legal ruling.

Much of this firm’s profits depend on its market-leading treatment for opioid addiction, Suboxone Film. This tragic problem has reached epidemic proportions in the US, and rival pharmaceutical firms are clamouring to be allowed to sell generic alternatives to.

Indivior is seeking to protect its market share by suing rival firms for alleged patent violations. The stakes are high. Following the August’s legal defeat, management admitted that “a rapid and material loss of market share” could follow “within months” if a generic alternative was allowed onto the market.

Unsurprisingly, Indivior’s management isn’t going to give up without a fight. The firm plans to appeal the August ruling and announced on Friday that it had filed lawsuits against six rivals relating to a new patent that’s applicable to Suboxone Film.

A turnaround opportunity?

This battle may roll on for months or even years. In the meantime, Indivior’s business is doing quite well. Net revenue rose by 5% during the first half of the year, with operating profit up by 23% to $244m. Earnings per share are expected to climb by 9% to 38 cents, putting the stock on a modest forecast P/E of about 10.

Although there’s no dividend, this could change if Indivior manages to secure lasting legal protection for Suboxone Film. Securing this revenue stream could result in strong cash generation and rising profits. The risk is that there’s no way to know how this will turn out, making this stock quite speculative.

Has this sell-off gone too far?

Indivior is too speculative for me, but I am interested in FTSE 100 motor insurance group Admiral Group (LSE: ADM). This firm is splashing out on TV advertising at the moment to promote the launch of its combined home and motor insurance product.

Management may be keen to find a new source of income, after profit growth was crushed by higher costs during the first half of the year. Investors have turned wary since the firm’s half-year results revealed that despite a 15% increase in turnover during the six months to 30 June, pre-tax profit only rose by 2% during the same period.

The shares have fallen by 20% since August, but I think this sell-off may have gone too far. Last week the government announced that the Ogden rate — which affects compensation payouts — will be reviewed after last year’s drastic cut. This decision is expected to result in lower personal injury payout costs for UK insurers and should boost profit margins.

This 6% yield looks safe to me

Admiral’s customer numbers rose by 13% during the first half. If this performance can be maintained, then I’d expect a solid full-year performance.

Analysts expect the firm to return a total of 107.9p to shareholders this year, giving a forecast yield of 6%. This looks affordable to me, based on last year’s free cash flow. I’d rate Admiral stock as a buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

FTSE shares: the perfect ‘get rich slow’ idea?

As a long-term investor, Christopher Ruane reckons the FTSE 100 could offer him the foundations to create stock market wealth.…

Read more »

Investing Articles

Here’s how an investor in their 30s could aim to turn a £10k ISA into £132,676 by retirement

Christopher Ruane explains how someone with a 30-year investing timeframe could aim to increase an ISA stuffed with blue-chip shares…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 5 years ago is now worth…

Rolls-Royce shares have made a lot of investors very rich as they push to new heights. Dr James Fox explores…

Read more »

Investing Articles

£20k split between these 2 FTSE value stocks 1 month ago is now worth…

Harvey Jones has had his eye on two value stocks from the FTSE 100. Suddenly they've both taken off at…

Read more »

Investing Articles

Gold’s hit record highs – and these former penny shares have soared over 115%!

After gold recently hit record highs, it may be no surprise that two former penny shares focused on the yellow…

Read more »

Investing Articles

£20k in a Stocks and Shares ISA? Here’s how to target passive income of £633 a month

Christopher Ruane explains how an investor could turn a Stocks and Shares ISA into a passive income goldmine with a…

Read more »

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

How much passive income could I earn from dividends by investing £5,000 a year in the UK stock market?

When starting out it's often the first thing investors ask: how much passive income can I earn? Mark Hartley attempts…

Read more »

Young woman holding up three fingers
Investing Articles

3 steps to start investing with under £300

Christopher Ruane walks through a trio of steps that someone who wants to start investing with just a few hundred…

Read more »